证券代码：688091 证券简称：上海谊众 公告编号：2025-045 上海谊众药业股份有限公司 关于股份回购实施结果暨股份变动的公告 （二）2025 年 9 月 12 日，公司召开了第二届董事会第十二次会议，审议通过 了《关于以集中竞价交易方式回购公司股份方案的议案》，同意将该议案提交股东 会审议。 （三）本次回购股份目的为：为维护公司价值及股东权益，符合《上海证券交 易所上市公司自律监管指引第 7 号——回购股份》第二条中连续 20 个交易日内公 司股票收盘价格跌幅累计达到 20%的情形。 （四）上述提议时间、程序和董事会审议程序等均符合《上市公司股份回购规 则》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定。 （五）2025 年 9 月 29 日，公司召开了 2025 年第一次临时股东会，审议通过 了《关于以集中竞价交易方式回购公司股份方案的议案》，详情请参阅公司于 2025 年 9 月 30 日披露的《2025 年第一次临时股东会决议公告》（公告编号：2025-040）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准 ...

Core Viewpoint - Shanghai Yizhong (688091.SH) has completed its planned share repurchase, reaching the upper limit of the expected repurchase amount [1] Summary by Categories Share Repurchase Details - The company has repurchased a total of 630,600 shares, which accounts for 0.3051% of the total share capital [1] - The total amount spent on the repurchase is 34.996 million yuan, excluding transaction fees [1] - The lowest price for the repurchased shares was 53.52 yuan per share, while the highest price was 58.91 yuan per share [1]

Core Viewpoint - Shanghai Yizhong (688091.SH) has completed its share repurchase program, reaching the upper limit of the expected repurchase amount [1] Summary by Categories Share Repurchase Details - The company has repurchased a total of 630,600 shares, which accounts for 0.3051% of the total share capital [1] - The actual amount spent on the repurchase is 34.996 million yuan, excluding transaction fees [1] - The lowest price for the repurchased shares was 53.52 yuan per share, while the highest price was 58.91 yuan per share [1]

Group 1 - The core viewpoint of the article highlights a collective decline in the A-share market for innovative drug concept stocks, with significant drops in several companies [1] Group 2 - Changshan Pharmaceutical experienced a decline of over 19%, with a total market capitalization of 51.7 billion and a year-to-date increase of 181.54% [2] - Zicheng Pharmaceutical and Baiyang Pharmaceutical both fell by over 7%, with market capitalizations of 6.984 billion and 13.3 billion respectively, and year-to-date increases of 68.53% and 9.05% [2] - Other companies such as Bibete-U, Kangchen Pharmaceutical, and Kanghong Pharmaceutical saw declines exceeding 5%, with market capitalizations of 14.3 billion, 28.8 billion, and respective year-to-date increases of 79.30% and 62.53% [2] - The article also notes that MACD golden cross signals have formed, indicating potential upward momentum for some stocks [1]

Core Viewpoint - Shanghai Yizhong reported significant growth in both revenue and net profit for the third quarter of 2025, driven primarily by the strong sales of its core product, paclitaxel micelles [1] Financial Performance - The company's total revenue for the first three quarters of 2025 reached 243 million yuan, representing a year-on-year increase of 43.4% [1] - The net profit attributable to shareholders was 50.66 million yuan, up 46.1% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 48.29 million yuan, reflecting a 55.4% increase compared to the previous year [1] - The operating cash flow net amount was -21.42 million yuan, a decline of 202.7% year-on-year [1] - The earnings per share (EPS) on a fully diluted basis was 0.2451 yuan [1] Quarterly Highlights - In the third quarter, the company achieved a revenue of 82.82 million yuan, marking a 73.7% increase year-on-year [1] - The net profit attributable to shareholders for the third quarter was 12.65 million yuan, a remarkable increase of 7751.8% year-on-year [1] - The net profit after deducting non-recurring gains and losses turned around from a loss of 2.08 million yuan in the same period last year to a profit of 11.24 million yuan [1] - The EPS for the third quarter was 0.0612 yuan [1] Product Performance - The sales volume of the core product, paclitaxel micelles, increased by 682% compared to the same period last year, significantly contributing to the growth in revenue and total profit [1] - The company's research and development investment rose to 25.74 million yuan, accounting for 31.08% of total revenue [1]

Key Highlights - Cambridge Technology currently does not produce chips containing CPO technology [1] - TCL Technology plans to invest 29.5 billion yuan in the construction of an 8.6-generation printed OLED production line [1] - Huakang Clean has won the bid for a "medical service construction project" [1] - Aotewei intends to acquire an 8.99% stake in its subsidiary Songci Electromechanical [1] - Shanghai Yizhong plans to repurchase shares worth 30 million to 35 million yuan [1] - Huaton Co. reported a pig sales revenue of 338 million yuan in August [1] - Tianma Technology has accumulated approximately 11,921.59 tons of eel out of the pool from January to August [1] - Mars Man's controlling shareholder plans to reduce holdings by no more than 2.94% [1] - Zhiwei Intelligent's actual controller plans to reduce holdings by no more than 2.9749% [1] - Donglin Investment plans to reduce holdings in Jin'an Guoji by no more than 2.878% [1] - Zhonglun New Materials intends to issue convertible bonds not exceeding 1.068 billion yuan [1] - Tuojing Technology plans to raise no more than 4.6 billion yuan through a private placement [1] Investment Projects - TCL Technology (000100.SZ) plans to invest 29.5 billion yuan in the construction of an 8.6-generation printed OLED production line [1] - Guangdong Jianke (301632.SZ) intends to invest in the implementation of the second phase of the Guangdong Jianke·Zhongshan Smart Gathering Project [1] - Nanfeng Co. (300004.SZ) plans to invest 50 million yuan in fixed assets for a 3D printing service project [1] Contracts and Acquisitions - Huakang Clean (301235.SZ) has won the bid for a "medical service construction project" [1] - Aotewei (688516.SH) intends to acquire an 8.99% stake in its subsidiary Songci Electromechanical [1] - Tianhua New Energy (300390.SZ) plans to acquire a 75% stake in Suzhou Tianhua Times [1] Share Buybacks - Chuangyuan Co. (300703.SZ) plans to repurchase 1.55% to 2.05% of its shares [2] - Yishitong (688733.SH) intends to repurchase shares worth 30 million to 55 million yuan [2] - Shanghai Yizhong (688091.SH) plans to repurchase shares worth 30 million to 35 million yuan [2] Operational Data - Huaton Co. (002840.SZ) reported a pig sales revenue of 338 million yuan in August [2] - Tianma Technology (603668.SH) has accumulated approximately 11,921.59 tons of eel out of the pool from January to August [2] Shareholding Changes - Sudda Co. (001277.SZ) plans to reduce holdings by no more than 3% [2] - Mars Man (300894.SZ) plans to reduce holdings by no more than 2.94% [2] - Zhiwei Intelligent (001339.SZ) plans to reduce holdings by no more than 2.9749% [2] - Jin'an Guoji (002636.SZ) plans to reduce holdings by no more than 2.878% [2] Other Financial Activities - China Merchants Shekou (001979.SZ) plans to issue preferred shares to raise no more than 8.2 billion yuan for real estate project construction [2] - Zhonglun New Materials (301565.SZ) intends to issue convertible bonds not exceeding 1.068 billion yuan [2] - Keli'er (002892.SZ) plans to raise no more than 1.006 billion yuan through a private placement [2] - Tuojing Technology (688072.SH) plans to raise no more than 4.6 billion yuan through a private placement [2]

Core Insights - The company reported a significant increase in revenue and net profit for the third quarter of 2025, indicating strong financial performance [1] Financial Performance - The company achieved a revenue of 82,820,176.44 yuan in the third quarter, representing a year-on-year growth of 73.68% [1] - The net profit attributable to shareholders reached 12,654,964.95 yuan, showing an extraordinary year-on-year increase of 7751.84% [1]

Core Viewpoint - Shanghai Yizhong (688091.SH) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong business performance and growth potential [1] Financial Performance - The total operating revenue for the first three quarters reached 243 million yuan, representing a year-on-year growth of 43.35% [1] - The net profit attributable to shareholders was 50.66 million yuan, showing a year-on-year increase of 46.12% [1] - The basic earnings per share stood at 0.25 yuan [1]

证券代码：688091 证券简称：上海谊众 公告编号：2025-044 董事会认为：公司 2025 年第三季度报告的编制和审议程序符合相关法律法规 及《公司章程》等内部规章制度的规定；公司 2025 年第三季度报告的内容与格式 符合相关规定，公允地反映了公司 2025 年第三季度的业绩情况与财务状况等事项； 报告的编制过程中，未发现公司参与报告编制和审议的人员有违反保密规定的行 为；董事会全体成员保证公司 2025 年第三季度报告披露的信息真实、准确、完整， 不存在任何虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和 完整性依法承担法律责任。 表决情况：赞成 6 票，反对 0 票，弃权 0 票。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)披露的《上海 谊众药业股份有限公司 2025 年第三季度报告》。 第二届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海谊众药业股份有限公司（以下简称"公司"）第二届董事会第十三次会议（以 下 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥82,820,176.44, an increase of 73.68% compared to the same period last year[4] - The net profit attributable to shareholders was ¥12,654,964.95, reflecting a significant increase of 7,751.84% year-on-year[4] - The total profit for the period was ¥9,157,792.73, with a year-to-date profit of ¥49,323,128.76, up 29.46% compared to the previous year[4] - The basic earnings per share for the year-to-date period was ¥0.25, an increase of 47.06% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses for the year-to-date period was ¥48,294,916.14, up 55.38% year-on-year[4] - Total operating revenue for the first three quarters of 2025 reached CNY 243,127,581.90, a significant increase of 43.3% compared to CNY 169,608,230.26 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 50,658,773.25, representing a 46.2% increase from CNY 34,670,092.06 in the previous year[20] - Basic and diluted earnings per share for the period were both CNY 0.25, compared to CNY 0.17 in the same period of 2024[21] Research and Development - Research and development expenses amounted to ¥25,737,658.21 for the quarter, representing a 157.01% increase year-on-year, and accounting for 31.08% of operating revenue[5] - Research and development expenses increased to CNY 54,502,662.62, up 115.5% from CNY 25,344,606.05 year-over-year[19] Assets and Liabilities - The total assets of the company increased to ¥1,543,666,261.43, a growth of 6.61% from the end of the previous year[5] - Total current assets as of September 30, 2025, amount to ¥690,562,425.53, a decrease from ¥776,207,087.54 as of December 31, 2024[16] - Total liabilities amounted to CNY 82,755,956.72, compared to CNY 42,971,884.05 in the previous year, indicating a growth of 92.7%[18] - Total equity attributable to shareholders reached CNY 1,460,910,304.71, an increase from CNY 1,405,020,800.85 in the previous year[18] Cash Flow - The cash flow from operating activities showed a net outflow of ¥21,421,543.09 year-to-date, reflecting a decrease of 202.67% compared to the previous year[4] - Cash inflows from operating activities totaled CNY 184,721,578.25, down from CNY 201,750,223.36 in the same period of 2024[23] - The net cash flow from operating activities was -21,421,543.09, a decrease from 20,865,363.56 in the previous period, indicating a significant decline in operational performance[24] - Cash outflows from operating activities totaled 206,143,121.34, compared to 180,884,859.80 in the prior period, reflecting an increase of approximately 13.9%[24] - The net cash flow from investing activities was -557,429,698.76, worsening from -168,798,149.82 year-over-year, highlighting increased investment expenditures[24] - Cash inflows from investing activities amounted to 4,423,656,160.38, up from 2,911,837,099.66, representing a growth of approximately 51.7%[24] - Total cash outflows from investing activities reached 4,981,085,859.14, compared to 3,080,635,249.48, indicating a rise of about 61.7%[24] - The net cash flow from financing activities was 2,588,963.52, a recovery from -110,822,617.12 in the previous period, suggesting improved financing conditions[24] - The total cash and cash equivalents at the end of the period were 68,144,410.98, a significant decrease from 651,130,264.21, reflecting liquidity challenges[25] - The cash and cash equivalents net increase was -576,262,278.33, compared to -258,755,403.38 in the prior period, indicating worsening cash flow management[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,053[12] - The largest shareholder, Zhou Jinsong, holds 40,127,058 shares, accounting for 19.41% of total shares[12]